Cancer clinical trials in the region Bretagne

200 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 3 Endometrial cancer #NCT06952504 #2024-519331-42-00

[TroFuse-033] Étude comparant le SACITUZUMAB TIRUMOTECANen association avec le PEMBROLIZUMAB et le pembrolizumab seul chez des participantes atteintes d'un cancer de l'endomètre pMMR

Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Locally Advanced Metastatic MSS/pMMR None Systemic Treatment-Naive

MSI/dMMR Immunotherapy Antibody Drug Conjugates (ADC) Immunotherapy Antibody Drug Conjugates (ADC)

Hôpital Privé des Côtes d'Armor (Plérin)

Merck Sharp & Dohme LLC

Phase 3 Breast cancer #NCT07062965

Une étude visant à en savoir plus sur le médicament expérimental appelé PF-07248144 en association avec le fulvestrant chez les personnes atteintes d'un cancer du sein avancé ou métastatique HR-positif et HER2-négatif ayant progressé après une ligne de traitement antérieure.

HER2 Negative HR Positive Locally Advanced Metastatic None 1 2 Targeted therapy Systemic Treatment-Naive Targeted therapy

Chemotherapy Antibody Drug Conjugates (ADC) Chemotherapy Antibody Drug Conjugates (ADC)

Centre Eugene Marquis (Rennes)

Pfizer

Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06819007

[DESTINY-Ovarian01] Étude du trastuzumab deruxtecan associé au bévacizumab versus bévacizumab en monothérapie pour le traitement d'entretien de première ligne du cancer de l'ovaire exprimant HER2

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Clear cell carcinoma Mucinous carcinoma Other epithelial ovarian cancer Stage III Stage IV Locally Advanced Metastatic HER2 None Chemotherapy Targeted therapy

BRCA 1/2

Centre Eugene Marquis (Rennes)

Daiichi Sankyo

Phase 3 Lung cancer #NCT06890598

[SUNRAY-02] Étude de l'OLOMORASIB en association avec les soins standard chez des participants atteints d'un cancer du poumon non à petites cellules avec mutation KRAS G12C réséquée ou non résécable - Partie A

NSCLC (Non-Small Cell Lung Cancer) Localized Locally Advanced KRAS G12C PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Surgery Immunotherapy Chemotherapy

ALK EGFR